Connect with the future of healthcare
Nanobots Therapeutics is a pre-clinical stage biotech company dedicated to the development of innovative therapies using nanorobots capable of self-propelling in body fluids and crossing complex biological barriers. These nanovehicles enable the delivery of treatments directly to target tissue, including solid tumours. Our first therapeutic indication is bladder cancer.
Prototype/preclinical
5.500.000€
2029-2030
Biotechnology
8.3%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
Founded in January 2023, Nanobots Therapeutics is a spin-off of the Institute for Bioengineering of Catalonia (IBEC) and the Catalan Institution for Research and Advanced Studies (ICREA). The company is developing a new nanobot-based drug delivery platform called Therapeutics in Motion (MotionTx). These nanobots are self-propelled nanoparticles capable of delivering drugs to target tissues, e.g. for the treatment of different solid tumours.
The technology was born in the Smart NanoBio Devices lab (IBEC), led by Professor Samuel Sánchez Ordóñez, an international benchmark in nanomotors and one of the few experts to demonstrate real medical applications in vivo.
Nanobots’ first focus is on non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of cases of this type of cancer. It causes 45,000 deaths per year in Europe and has a high recurrence rate (60%), making it one of the most expensive cancers to treat (€170,000/case). The standard treatment is bacillus Calmette-Guérin (BCG), but more than 40% of patients do not respond well to this therapy.
In preclinical studies in mice, nanobots have shown active penetration into bladder tumours, reducing tumour size by up to 90% with a single local application.
The company’s technology platform, MotionTx, holds an exclusive patent from IBEC and ICREA and stands out from other similar options. MotionTx’s nanobots are biocompatible, move autonomously using the body’s natural resources, and can be produced on an industrial scale. These features allow the nanobots to deliver drugs more effectively and safely in bladder tumours, especially in the treatment of NMIBC.
Although NBT-101’s first therapeutic programme is targeted at NMIBC, it has the potential to expand to other relevant indications that represent an unmet medical need. The goal is to develop the treatment to early stage (phase I/IIa) and then license it to a large pharmaceutical company that can bring it to market. Co-development agreements will also be sought to explore other medical applications of nanobots.
Since its founding, Nanobots Therapeutics has raised €2 million in public and private funding. The company is currently seeking an additional €500,000, ideally €1 M, to complete preclinical studies of NBT-101 and move towards first-in-human trials planned for 2028. Next steps include efficacy testing in animal models and the development of a regulatory and manufacturing plan.
Nanobots Therapeutics presents an innovative solution for the treatment of bladder cancer, a critical area with a high recurrence rate. Self-propelled nanorobot technology represents a breakthrough in drug delivery, enabling precise and effective delivery across biological barriers.
These nanobots have demonstrated their ability to penetrate bladder tumours and reduce their size by 90% with a single application. This efficacy, coupled with preclinical studies showing a promising safety profile, positions Nanobots as a key player in the delivery of intravesical therapies.
Nanobots Therapeutics has a multidisciplinary team with expertise in bioengineering and nanomedicine, allowing them to explore applications beyond bladder cancer. The company is in a growth phase and is positioned to take advantage of opportunities in a growing market with high demand for effective solutions.
Capital Cell believes that the investment in Nanobots Therapeutics represents a strategic opportunity with high return potential, addressing a critical medical need and improving the quality of life for patients.
Nanobots may encounter significant challenges in securing the necessary regulatory approvals for new treatments. This approval process has historically proven to be lengthy and complex, involving extensive testing and documentation. As a result, these hurdles could ultimately delay their entry into the market, which in turn may hinder their potential for growth and development in the rapidly evolving field of medicine.
Already have an account? Please login here .
